Persistent release of noradrenaline caused by anticancer drug 4'-epidoxorubicin in rat tail artery in vitro

European Journal of Pharmacology

Volumn 356, Issue 1, 1998, Pages 25-30

  Sakai, Toyohiko ^a   Inagaki, Rika ^a   Taniguchi, Takanobu ^a   Shinozuka, Kazumasa ^b   Kunitomo, Masaru ^b   Hayashi, Nobushige ^a   Ishii, Yasushi ^a   Muramatsu, Ikunobu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Kwansei Gakuin University   (Japan)

Author keywords

Anthracycline; Artery; Noradrenaline; Rat; Sympathetic nerve

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; CIMETIDINE; COCAINE; EPIRUBICIN; NORADRENALIN; PRAZOSIN; TETRODOTOXIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROSTIMULATION; HORMONE RELEASE; IN VITRO STUDY; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SYMPATHETIC NERVE; TAIL ARTERY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ARTERIES; CALCIUM; COCAINE; CULTURE MEDIA; ELECTRIC STIMULATION; EPIRUBICIN; MALE; MUSCLE TONUS; NOREPINEPHRINE; PRAZOSIN; RATS; RATS, WISTAR; TAIL; TETRODOTOXIN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0032575615     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00505-6     Document Type: Article

References (19)

1. Bristow M.R., Sageman W.S., Scott R.H., Billingham M.E., Bowden R.E., Kernoff R.S., Snidow G.H., Daniel J.R. Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J. Cardiovasc. Pharmacol. 2:1980;487-515.
2. Bristow M.R., Minobe W.A., Billingham M.E., Marmor J.B., Johnson G.A., Ishimoto B.M., Sageman W.S., Daniels J.R. Anthracycline-associated cardiac and renal damage in rabbits. Lavo. Invest. 45:1981;157-168.
3. Chen Z.M., Colombo T., Conforti L., Donelli M.G., Fiedorowicz R.J., Marchi S., Paolini A., Riva E., Zuanetti G., Latini R. Effects of three new anthracyclines and doxorubicin on the rat isolated heart. J. Pharm. Pharmacol. 39:1987;947-950.
4. Dasan L., Steven R.V. Inhibition of nitric oxide synthase by antineoplastic anthracyclines. Biochem. Pharmacol. 47:1994;2111-2112.
5. Ferrans V.J. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat. Rep. 62:1978;955-961.
6. Fleming W.W. Supersensitivity in smooth muscle; introduction and historical perspective. Federation Proc. 34:1975;1969-1970.
7. Hüsken B.C.P., de Jong J., Onderwater B.B.R.C.A., Vijgh Aalt Bast W.J.F. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother. Pharmacol. 37:1995;55-62.
8. Ishii R., Shinozuka K., Kunimoto M., Hashimoto T., Takeuchi K. Characterization of the facilitatory prejunctional purinoceptor on adrenergic nerves of the rabbit ear artery. J. Pharmacol. Exp. Ther. 273:1995;1390-1395.
9. Iwai M., Shimizu T. Exaggeration of acute liver damage by hepatic sympathetic nerves and circulating catecholamines in perfused liver of rats treated with D-galactosamine. Hepatology. 23:1996;524-529.
10. Lenaz L., Page J.A. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat. Rev. 3:1976;111-120.
11. Muramatsu I., Oshita M., Yamanaka K. Selective alpha-2 blocking action of DG-5128 in the dog mesenteric artery and rat vas deferens. J. Pharmacol. Exp. Ther. 227:1983;194-198.
12. Olson R.D., Boerth R.C., Gerber J.G., Nies A.S. Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci. 29:1981;1393-1401.
13. Prozato P., Bertelli G., Bruna F., Tani F., Vaira F., Vanoli M., Vigani A. Intensified M-VEC chemotherapy with G-CSF support as outpatient treatment for advanced bladder cancer. Anticancer Res. 17:1997;2325-2328.
14. Rona G. Catecholamine cardiotoxicity. J. Mol. Cell. Cardiol. 17:1985;291-306.
15. Sakai T., Muramatsu I., Hayashi N., Ishii Y. Inhibition of NO synthase induction by an anticancer drug 4′-epidoxorubicin in rats. Gen. Pharmacol. 27:1996;1367-1372.
16. Schömig A., Kurz T., Richard G. Sympatho-adrenergic activation of the ischemic myocardium and arrhythmogenic impact. Herz. 20:1995;169-186.
17. Seki H., Kimura M., Kamura T., Miura T., Yoshimura N., Sakai K. Hepatic perfusion abnormalities during treatment with hepatic arterial infusion chemotherapy; value of CT arteriography using an implantable port system. J. Comput. Assist. Tomogr. 20:1996;343-348.
18. Uchida H., Ohishi H., Matsuo N., Nishimine K., Ohue S., Nishimura Y., Maeda M., Yoshioka T. Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelform particles for hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 13:1990;140-145.
19. Wall E., Rutgers E.J.T., Holtcamp M.J., Baars J.W., Schornagel J.H., Peterse J.L., Beijnen J.H., Rodenhuis S. Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. Brit. J. Cancer. 73:1996;1080-1085.